Literature DB >> 15115634

Anti-inflammatory agents for the treatment of musculoskeletal pain and arthritis.

Keri L Fakata1.   

Abstract

Pain produced by musculoskeletal disorders commonly misconceived as having mechanical etiology often is caused by inflammatory mechanisms. Simple analgesics (ie, those that lack anti-inflammatory action) often are used to treat musculoskeletal pain when an anti-inflammatory analgesic may be more effective for the painful condition. This review addresses the anti-inflammatory agents available for the symptomatic management of common inflammatory musculoskeletal conditions including osteoarthritis, rheumatoid arthritis, and low back pain.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15115634     DOI： 10.1007/s11916-004-0048-2

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN： 1534-3081


  26 in total

1.  Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.

Authors:  P Brooks; P Emery; J F Evans; H Fenner; C J Hawkey; C Patrono; J Smolen; F Breedveld; R Day; M Dougados; E W Ehrich; J Gijon-Baños; T K Kvien; M H Van Rijswijk; T Warner; H Zeidler
Journal:  Rheumatology (Oxford)       Date:  1999-08       Impact factor: 7.580

2.  Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.

Authors:  Gregory P Geba; Arthur L Weaver; Adam B Polis; Mary E Dixon; Thomas J Schnitzer
Journal:  JAMA       Date:  2002-01-02       Impact factor: 56.272

Review 3.  Can we conquer pain?

Authors:  Joachim Scholz; Clifford J Woolf
Journal:  Nat Neurosci       Date:  2002-11       Impact factor: 24.884

4.  A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.

Authors:  R Day; B Morrison; A Luza; O Castaneda; A Strusberg; M Nahir; K B Helgetveit; B Kress; B Daniels; J Bolognese; D Krupa; B Seidenberg; E Ehrich
Journal:  Arch Intern Med       Date:  2000-06-26

5.  A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.

Authors:  K E Truitt; R S Sperling; W H Ettinger; M Greenwald; L DeTora; Q Zeng; J Bolognese; E Ehrich
Journal:  Aging (Milano)       Date:  2001-04

6.  Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.

Authors:  G W Cannon; J R Caldwell; P Holt; B McLean; B Seidenberg; J Bolognese; E Ehrich; S Mukhopadhyay; B Daniels
Journal:  Arthritis Rheum       Date:  2000-05

7.  COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.

Authors:  N V Chandrasekharan; Hu Dai; K Lamar Turepu Roos; Nathan K Evanson; Joshua Tomsik; Terry S Elton; Daniel L Simmons
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

8.  Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis.

Authors:  Grace H Lo; Michael LaValley; Timothy McAlindon; David T Felson
Journal:  JAMA       Date:  2003-12-17       Impact factor: 56.272

Review 9.  Mechanisms of pain in arthritis.

Authors:  Hans-Georg Schaible; Andrea Ebersberger; Gisela Segond Von Banchet
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

10.  Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

Authors:  P Emery; H Zeidler; T K Kvien; M Guslandi; R Naudin; H Stead; K M Verburg; P C Isakson; R C Hubbard; G S Geis
Journal:  Lancet       Date:  1999 Dec 18-25       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.